Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Other Accumulated Expenses (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Other Accumulated Expenses for 4 consecutive years, with $741000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 32.33% to $741000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $741000.0 through Dec 2025, down 32.33% year-over-year, with the annual reading at $741000.0 for FY2025, 32.33% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $741000.0 at Mereo BioPharma, up from $622000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $3.4 million in Q2 2024, with the low at $622000.0 in Q3 2025.
  • Average Other Accumulated Expenses over 4 years is $1.3 million, with a median of $957500.0 recorded in 2023.
  • Peak annual rise in Other Accumulated Expenses hit 24.51% in 2025, while the deepest fall reached 77.38% in 2025.
  • Over 4 years, Other Accumulated Expenses stood at $1.1 million in 2022, then fell by 4.67% to $1.0 million in 2023, then increased by 7.25% to $1.1 million in 2024, then crashed by 32.33% to $741000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $741000.0, $622000.0, and $777000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.